ECSP034798A - Amidas de acido benzofuran-2-carboxílico sustituidas - Google Patents

Amidas de acido benzofuran-2-carboxílico sustituidas

Info

Publication number
ECSP034798A
ECSP034798A EC2003004798A ECSP034798A ECSP034798A EC SP034798 A ECSP034798 A EC SP034798A EC 2003004798 A EC2003004798 A EC 2003004798A EC SP034798 A ECSP034798 A EC SP034798A EC SP034798 A ECSP034798 A EC SP034798A
Authority
EC
Ecuador
Prior art keywords
diseases
treatment
cerebral
disorders
amidas
Prior art date
Application number
EC2003004798A
Other languages
English (en)
Inventor
Dieter Dorsch
Gerd Bartoszyk
Henning Boettcher
Amsterdam Christoph Van
Wilfried Rautenberg
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP034798A publication Critical patent/ECSP034798A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

donde D, R1, R2 y n tienen los significados mencionados en la reivindicación 1, son potentes agonistas de 5-HT1A e inhibidores de la reabsorción de 5-HT y son apropiados para el tratamiento de depresiones, estados de angustia, ataques de pánico, trastornos obsesivos enfermedades psiquiátricas, infartos cerebrales, isquemia cerebral, estados de ansiedad, de efectos secundarios del tratamiento de la hipertensión sanguínea, para la prevención y el tratamiento de enfermedades cerebrales, acromegalia, hipogonadismo, amenorrea secundaria, síndrome premenstrual, lactancia puerperal no deseada, dolor, trastornos del sueño, narcolepsia, enfermedades bipolares, manías, demencia, enfermedades adictivas, disfunciones sexuales, trastornos de la alimentación, obesidad o fibromialgia.
EC2003004798A 2001-03-14 2003-10-09 Amidas de acido benzofuran-2-carboxílico sustituidas ECSP034798A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10112151A DE10112151A1 (de) 2001-03-14 2001-03-14 Substituierte Benzofuran-2-carbonsäureamide

Publications (1)

Publication Number Publication Date
ECSP034798A true ECSP034798A (es) 2003-12-01

Family

ID=7677358

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004798A ECSP034798A (es) 2001-03-14 2003-10-09 Amidas de acido benzofuran-2-carboxílico sustituidas

Country Status (20)

Country Link
US (1) US7244846B2 (es)
EP (1) EP1368346A1 (es)
JP (1) JP4485743B2 (es)
KR (1) KR20030080083A (es)
CN (1) CN1244578C (es)
AR (1) AR035782A1 (es)
BR (1) BR0208040A (es)
CA (1) CA2440726C (es)
CZ (1) CZ20032712A3 (es)
DE (1) DE10112151A1 (es)
EC (1) ECSP034798A (es)
EE (1) EE200300447A (es)
HU (1) HUP0303449A3 (es)
IL (1) IL157889A0 (es)
MX (1) MXPA03008140A (es)
PL (1) PL362844A1 (es)
RU (1) RU2003129057A (es)
SK (1) SK12492003A3 (es)
WO (1) WO2002083666A1 (es)
ZA (1) ZA200307966B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
DE10305739A1 (de) * 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
DE10306941A1 (de) * 2003-02-18 2004-08-26 Merck Patent Gmbh Benzofuranoxyethylamine
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
DE102005019670A1 (de) * 2005-04-26 2006-11-02 Merck Patent Gmbh Verfahren zur Herstellung von (5-(4-[4-(5-Cyano-3-indolyl)-butyl)-1-piperazinyl)-benzofuran-2-carboxamid
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
DE102006060597A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Verfahren zur Herstellung von Benzofuran-2-carboxamiden
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
WO2009112139A1 (en) * 2008-03-14 2009-09-17 Merck Patent Gmbh, Azaindole compounds for treatment of central nervous system disorders
EP2110374A1 (en) * 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
KR101361145B1 (ko) * 2011-03-10 2014-02-12 한국화학연구원 신규한 벤조퓨란-2-카르복사미드 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도
CN103570698B (zh) * 2012-08-01 2016-08-03 江苏恩华药业股份有限公司 用于制备维拉佐酮的化合物及其中间体和应用
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
CN106243088B (zh) 2015-06-03 2019-01-04 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders

Also Published As

Publication number Publication date
DE10112151A1 (de) 2002-09-19
EE200300447A (et) 2003-12-15
JP4485743B2 (ja) 2010-06-23
CA2440726C (en) 2011-05-17
CN1244578C (zh) 2006-03-08
US7244846B2 (en) 2007-07-17
WO2002083666A1 (en) 2002-10-24
AR035782A1 (es) 2004-07-14
BR0208040A (pt) 2004-02-25
HUP0303449A3 (en) 2005-02-28
RU2003129057A (ru) 2005-04-10
US20050075269A1 (en) 2005-04-07
PL362844A1 (en) 2004-11-02
SK12492003A3 (sk) 2004-03-02
JP2004527536A (ja) 2004-09-09
CZ20032712A3 (cs) 2004-01-14
IL157889A0 (en) 2004-03-28
EP1368346A1 (en) 2003-12-10
CN1494543A (zh) 2004-05-05
KR20030080083A (ko) 2003-10-10
MXPA03008140A (es) 2003-12-12
HUP0303449A2 (hu) 2004-01-28
ZA200307966B (en) 2005-01-13
CA2440726A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
DK1458713T3 (da) Indolinonderivater anvendelige som proteinkinaseinhibitorer
NO20054200L (no) Pyrazoler samt fremgangsmate for fremstilling derav
EA200300944A1 (ru) Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
CY1111138T1 (el) Πυραζολο-υποκατεστημενες αμινοετεροαρυλ ενωσεις ως αναστολεις κινασης πρωτεϊνης
MY151087A (en) Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
MXPA04004956A (es) Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central.
NO20064277L (no) 6-substituerte 2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C reseptoragonister
WO2001045730A3 (en) Tweak receptor
CA2534570A1 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
NO20012966D0 (no) Kondenserte 1,2,4-tiadiazinderivater, deres fremstilling og anvendelse
DE602006016965D1 (de) Il-17a- und il-17f-antagonisten und verwendungsverfahren
ATE359271T1 (de) Phenylderivate
DE60324544D1 (de) Muskarin antagonisten
BR0208040A (pt) Derivados de benzofuran-2-carboxamidas substituìdas
GB0504828D0 (en) Therapeutic agents
WO2003048333A3 (en) Endorepellin compositions and methods for inhibiting angiogenesis
EP1254662A3 (en) Methods and kits for treating depression or preventing deterioration of cognitive function
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
WO2002094196A3 (en) Method of treatment for cancers associated with elevated
NO20055741L (no) Nye kjemiske forbindelser
CY1106409T1 (el) Παραγωγα κινολινης
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
DK1532131T3 (da) Motilid-forbindelser